RVO
HomeMarketplace

Project cooperationUpdated on 1 September 2025

Precision oncology for advanced targeted therapies

Rositsa Jordanova

CEO and founder at Protyon

Groningen, Netherlands

About

We seek collaborators on lung, breast, or colorectal cancer projects, and aim to expand our technology to all types of advanced targeted therapies, including small-molecule drugs and immunotherapies. With expertise in tyrosine kinase inhibitors for EGFR-, BRAF-, and ALK-driven NSCLC, our software assesses mutation effects. Our technology is clinically validated and helps de-risk pipelines, assess novel mutations, and optimize cohort selection, improving drug development and patient outcomes.

Stage

  • Early

Type

  • Research
  • Financing

Organisation

Protyon

Company

Groningen, Netherlands

Similar opportunities